Posted 13th May 2020 by Liv Sewell
NASH is thought to affect 25% of the global population and is a primary risk factor for Hepatocellular carcinoma (HCC) – the second most common cause of cancer deaths worldwide. Understanding the aetiology of NAFLD progression, developing non-invasive diagnostic tests and developing treatments are urgent priorities.
Posted 29th April 2020 by Liv Sewell
You may have heard; humans are superorganisms. The human large intestine harbors tens of trillions of microbes, which equates to roughly 2 kg of cells. For reference, that’s how much your brain weighs! Within the gut microbiome, it is estimated that there are over 1,000 different species of bacteria.
Posted 28th October 2019 by Liv Sewell
Hepatocellular carcinoma (HCC) is the fifth most prevalent cancer and the second most common cause of cancer deaths worldwide. There is not currently a successful therapy to treat HCC in advanced stages. NASH is a primary risk factor for liver cancer.
Devanand Sarkar and his team have uncovered the molecular mechanisms leading to NASH and HCC, shedding light on the connections between obesity and cancer. He is leveraging this knowledge to develop targeted treatments for both NASH and advanced HCC. We asked him to give us a brief insight into his work ahead of his presentation at the 3rd Global NASH Congress, 2020.
Posted 21st December 2018 by Jane Williams
The burden of non-alcoholic fatty liver disease (NAFLD) continues to increase at an alarming rate. The prevalence of disease equals the prevalence of metabolic syndrome (nearly 30% of the adult population), and NASH-cirrhosis represents the second cause for entering the waiting list for liver transplantation, with/without associated primary liver cancer.
Posted 15th December 2017 by Jane Williams
Multifactorial diseases require a safe, multifunctional and integrated approach to treatment. Based on this recognition, a new class of therapeutics, called Defined Amino Acid Compositions (DAACs™), are being pioneered by Axcella Health.